Newsletters and Deep Dive digital magazine
Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following
Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic.
If we learned anything at CAR-TCR it’s that CAR-T therapies are still a relatively new treatment modality and innovation is happening along many different axes.
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho